Sera Prognostics, Inc.
HealthcareNASDAQ:SERA · NASDAQ Global Market
-$0.06 today
Vol 0.05M · Avg 0.07M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$57.0K of revenue converted into -$32.1M of net income for the selected period. Gross margin is -204.4% and net margin is -58742.4%, showing how much revenue survives after costs and taxes. EPS is $-0.65, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81.0K +5.2% | $77.0K -74.8% | $306.0K +14.2% | $268.0K +226.8% | $82.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $164.0K +100.0% | $82.0K -61.0% | $210.0K +8.8% | $193.0K +421.6% | $37.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$83.0K -1560.0% | -$5.0K -105.2% | $96.0K +28.0% | $75.0K +66.7% | $45.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | -102.5% -96.0pp | -6.5% -37.9pp | 31.4% +3.4pp | 28.0% -26.9pp | 54.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $13.2M -10.6% | $14.7M -3.3% | $15.2M +6.9% | $14.2M +29.3% | $11.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $23.3M +6.2% | $21.9M -11.3% | $24.7M -21.6% | $31.5M +28.9% | $24.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $36.4M -0.6% | $36.6M -8.2% | $39.9M -12.7% | $45.7M +29.0% | $35.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $940.0K +12.8% | $833.0K -7.4% | $900.0K +19.0% | $756.0K +14.7% | $659.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$31.0M +3.3% | -$32.0M +9.2% | -$35.3M +18.6% | -$43.4M -29.1% | -$33.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -38245.7% +3360.8pp | -41606.5% -30074.8pp | -11531.7% +4650.8pp | -16182.5% +24798.0pp | -40980.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$36.5M +0.4% | -$36.6M +8.0% | -$39.8M +12.8% | -$45.7M -29.0% | -$35.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -45066.7% +2511.3pp | -47577.9% -34564.5pp | -13013.4% +4020.9pp | -17034.3% +26130.3pp | -43164.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.6M +66.9% | $2.7M +67.5% | $1.6M +259.6% | $456.0K +214.5% | $145.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $9.0K -67.9% | $28.0K -49.1% | $55.0K -9.8% | $61.0K -91.8% | $746.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.6M +22.5% | $3.7M +4.4% | $3.6M +144.1% | $1.5M +279.8% | $386.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$31.9M +2.9% | -$32.9M +9.2% | -$36.2M +18.0% | -$44.2M -26.2% | -$35.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -39417.3% +3307.4pp | -42724.7% -30880.9pp | -11843.8% +4643.5pp | -16487.3% +26206.6pp | -42693.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$31.9M +2.9% | -$32.9M +9.2% | -$36.2M +18.0% | -$44.2M -26.2% | -$35.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -39417.3% +3307.4pp | -42724.7% -30880.9pp | -11843.8% +4643.5pp | -16487.3% +26206.6pp | -42693.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +32.3% | -$1 +14.7% | -$1 +18.9% | -$1 -21.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +32.3% | -$1 +14.7% | -$1 +18.9% | -$1 -21.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $47.7M +43.7% | $33.2M +6.3% | $31.2M +0.8% | $30.9M +0.6% | $30.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $47.7M +43.7% | $33.2M +6.3% | $31.2M +0.8% | $30.9M +0.6% | $30.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$80.59M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
SkyAI, Inc.
STSS
$47.61M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SERA generate?
Sera Prognostics, Inc. (SERA) reported $81,000.00 of revenue in fiscal 2025.
Is SERA profitable?
Sera Prognostics, Inc. (SERA) reported -$31,928,000.00 of net income, with a net margin of -39417.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.